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The Phase I/II clinical trial randomized patients to GVAX
immunotherapy (two prostate cancer cell lines that secrete
GM-CSF, Cell Genesys Inc.) alone or in combination with
non-myeloablative chemotherapy and adoptive transfer of
PBMC. Pre and week 11 aphereses were obtained to elutri-
ate monocytes and cryopreserve PBMC for immune moni-
toring. We used ProtoArrays (8,217 proteins spotted
arrays, Invitrogen) to evaluate the week 11 post treatment
antibody responses of 11 patients who completed this
IRB-approved DAMD-funded clinical trial for men with
androgen-independent prostate cancer. Analysis of pre
and week 11 sera identified increased antibody responses
to a number of proteins and the patients with an increase
in PSA-doubling time (PSA-DT) exhibited a strong
response to a significantly (p < 0.05) larger number of pro-
teins (mean = 60) than patients whose PSA-DT decreased
(mean = 22). Next we sought to determine whether the
genes targeted by the strong Ab responses were expressed
by the patient’s tumor. Since no post treatment tumor
biopsies were available, a fluorescence-activated cell sort-
ing (FACS) method was developed to isolate circulating
tumor cells from cryopreserved blood samples. Aphereses
products were thawed, stained with anti-EpCAM, anti-
CD45, anti-CD4, and anti-CD8 antibodies. EpCAM +ve
and CD4, CD8, CD45 -ve cells were sorted as CTC. RNA
was isolated from all CTC and amplified. Gene expression
profiling was performed using 35K oligonucleotide arrays.
Amplified RNA from CTCs were hybridized with Cy5 and
amplified normal prostate RNA were hybridized with Cy3
Dye. Data was analysed using madb (BIMAS/CBEL/CIT,
NCI). Gene expression profile was compared between pre
and post treatment CTCs. CTC expressed 1296-2369
genes at >1.5 fold compared to a normal prostate tissue
control. Current efforts are aimed at evaluating whether
targets of the antibody response were contained in the oli-
gonucleotide array and whether proteins for genes that
decreased in intensity were contained on the protein array.
The methods we describe may help assess whether a given
treatment is inducing strong immune response and
whether this immune response is sculpting the repertoire
of antigens expressed by the tumor. Such tests are cur-
rently not available and development of such a test may
aid the development and refinement of the novel combi-
nation immunotherapy strategies.
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